title: Exploring the biological basis of haemophilic joint disease: experimental studies.
abstract: Haemophilia has been recognized as the most severe among the inherited disorders of blood coagulation since the beginning of the first millennium. Joint damage is the hallmark of the disease. Despite its frequency and severity, the pathobiology of blood-induced joint disease remains obscure. Although bleeding into the joint is the ultimate provocation, the stimulus within the blood inciting the process and the mechanisms by which bleeding into a joint results in synovial inflammation (synovitis) and cartilage and bone destruction (arthropathy) is unknown. Clues from careful observation of patient material, supplemented with data from animal models of joint disease provide some clues as to the pathogenesis of the process. Among the questions that remain to be answered are the following: (i) What underlies the phenotypic variability in bleeding patterns of patients with severe disease and the development of arthropathy in some but not all patients with joint bleeding? (ii) What is the molecular basis underlying the variability? (iii) Are there strategies that can be developed to counter the deleterious effects of joint bleeding and prevent blood-induced joint disease? Understanding the key elements, genetic and/or environmental, that are necessary for the development of synovitis and arthropathy may lead to rational design of therapy for the targeted prevention and treatment of blood-induced joint disease.
authors: Department of Pediatrics, RUSH Hemophilia and Thrombophilia Center, Rush Children's Hospital, Chicago, IL 60612-3833, USA. lvalentino@rush.edu
authors: L A
authors: LA
authors: Valentino
authors: N
authors: N
authors: Hakobyan
authors: C
authors: C
authors: Enockson
authors: M L
authors: ML
authors: Simpson
authors: N C
authors: NC
authors: Kakodkar
authors: L
authors: L
authors: Cong
authors: X
authors: X
authors: Song
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D005169:Factor VIII / Q000627:therapeutic use; D006395:Hemarthrosis / Q000209:etiology / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007592:Joint Diseases / Q000209:etiology* / Q000503:physiopathology; D051379:Mice; D008958:Models, Molecular; D010641:Phenotype; D013585:Synovitis / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D005169:Factor VIII